

DAFTAR PUSTAKA

- Anonim, 2014, *Undang-Undang Republik Indonesia No. 18 Tahun 2014 tentang Kesehatan Jiwa disertai Penjelasannya*, Kemenkumham RI, Jakarta.
- Anonim, 2019, *Clozapin*, https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/drug_monograph/6-s2.0-142, diakses pada 1 November 2019.
- Baradero, M., Dayrit, W.M., Maratning, A., 2016, *Kesehatan Mental Psikiatri: Seri Asuhan Keperawatan*, Penerbit Buku Kedokteran EGC, Jakarta.
- Budden, F., & Sumerville, C., 2012, *Learning About Schizofrenia: Rays of Hope fourth revised edition*, Schizofrenia Society of Canada, Canada. pp 4-22.
- Cascio, M.T., Cella, M., Preti, A., Meneghelli, A., & Cocchi, A., 2012, Gender and Duration of Untreated Psychosis: A Systematic Review and Meta-analysis. *Early Intervention in Psychiatry*, 6(2), 115-127.
- Chathoth, V., Ramamurthy, P., Solomon, S., 2018, Clozapine-induced Insulin-resistant Hyperglycemia in a Diabetic Patient, *Indian Journal of Psychological Medicine*, 40(4), 375-377.
- Chou, I.J., Kuo, C.F., Huang, Y.S., Grainge, M.J., Valdes, A.M., See, L.C., Yu, K.H., Luo, S.F., Huang, L.S., Tseng, W.Y., Zhang, W., and Doherty, M., 2017, Familial Aggregation and Heritability of Schizophrenia and Co-aggregation of Psychiatric Illnesses in Affected Families, *Schizophrenia Bulletin*, Vol 43 no 5 pp. 1070-1078.
- Corroon E.B., 2005, A Review of the Neurodevelopmental Hypothesis of Schizophrenia, *Trinity Student Medical Journal*, Volume 6:Review Article, 39-43.
- Crismon, M.L., & Buckley, P.F., 2008, Schizophrenia, dalam Dipiro, J.T., Talbert, R.I., Yee, G.C., Matzke, G.R., Wells, B.G., & Posey, L.M., (Eds), *Pharmacotherapy A Pathophysiologic Approach*, Edisi 7, 1099-1230, McGraw Hill, Medical Publishing Division, New York.
- Crismon, M.L., Argo, T.R., & Buckley P.F., 2015, Schizophrenia, dalam Wells, B.G., Dipiro, J.T., Schwinghammer, T.L., DiPiro, C.V., *Pharmacotherapy Handbook*, Ninth Edition, Mc Graw Hill, New York, 731-736.

- Dean, K., & Murray, R.M., 2005, Environmental Risk Factors for Psychosis, *Dialogues Clin.*,7(1), 69-80.
- Depkes, 1993, *Pedoman Penggolongan dan Diagnosis Gangguan Jiwa di Indonesia III*, Departemen Kesehatan RI, Jakarta.
- Depkes, 2011, *Modul Pengobatan Rasional*, Kementerian Kesehatan RI, Jakarta, pp 1.
- Dewi, R., & Marchira, R., 2009, Riwayat Gangguan Jiwa Pada Keluarga Dengan Kekambuhan Pasien Skizofrenia di RSUP Sardjito Yogyakarta, *Berita Kedokteran Masyarakat*, 25(4), 176-179.
- Essock, S.M., Schooler, N.R., Stroup T.S., McEvory, J.P., Rojas, I., Jackson, C., Covell, N.H., 2011, Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy, *American Journal of Psychiatry*, 168(7), 702-708.
- Falkenburg, J., & Tracy, D.K., 2014, Sex and Schizophrenia: a Review of Gender Differences, *Psychosis: Psychological, Social and Integrative Approaches*, 6(1), 61-69.
- Fatemi S.H., & Folsom T.D., 2009, The Neurodevelopmental Hypothesis of Schizophrenia, Revisited, *Schizophrenia Bulletin*, Vol. 35 No. 3 pp, 528–548.
- Fazel, S., Zetterqvist, J., Larson, H., Langstrom, N., & Lichtenstein, P., 2014, Antipsychotics, Mood Stabilisers, and Risk of Violent Crime, *The Lancet*, 384(9949), 1206-1214.
- Gibson, A.P., Patel, N.C., Lauriello, J., & Buckley, P.F., 2008, Antipsychotic Combinations: Blind Step or Logical?, *Current Psychiatry*, 7(7), 41-53.
- Grover, S., Sahoo, S., Mahajan, S., 2017, Clozapine-induced Hypertension: A Case Report and Review of Literature, *Industrial Psychiatry Journal*, 26(1), 103-105.
- Hafner, H., Nowotny, B., 1995, Epidemiology of Early-Onset Schizophrenia, *Eur Arch Psychiatry Clin Neurosci*, 245, 80-92.
- Handayani, L., Febriani, Rahmadani, A., and Saufi, A., 2017, Faktor Risiko Kejadian Skizofrenia di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (DIY), *Humanitas*, Vol. 13 No 2, 135-148.
- Hariyani, Yuliasuti, F., and Kusuma, T.M., 2016, Pola Pengobatan Pasien Schizoprenia Program Rujuk Balik di Puskesmas Mungkid Periode Januari-Juni 2014, *Pharmaciana*, Vol 6 No.1, 63-70.

- Hawari, D., 2003, *Pendekatan Holistik Pada Gangguan Jiwa Skizofrenia*, Edisi 2, Balai Penerbit FKUI, Jakarta.
- Henderson, D.C., Daley, T.B., Kunkel, L., Rodrigues, S.M., Koul, P., Hayden, D., 2004, Clozapine and Hypertension: A Chart Review of 82 Patients, *The Journal of Clinical Psychiatry*, 65(5), 686-689.
- Hosak, L., 2013, New Findings in The Genetics of Schizophrenia, *World Journal of Psychiatry*, 3(3), 57-61.
- Ikawati, Z., 2011, *Farmakoterapi Penyakit Sistem Saraf Pusat*, Cetakan I, Bursa Ilmu, Yogyakarta, pp 249-282.
- Ingram, I.M., Timbury, G.C., Mowbray, R.M., 1993, *Catatan Kuliah Psikiatri*, Edisi IV, 51-58, EGC, Jakarta.
- Iqbal, M.M., Rahman, A., Husain, Z., Mahmud, S.Z., Ryan, W.G., and Feldman J.M., 2003, Clozapine: A Clinical Review of Adverse Effects and Management, *Annals of Clinical Psychiatry*, Vol. 15, 33-48.
- Iqbal, M.M., Swati, S., Aneja, A., Iqbal, M.T., Aneja, E., Haque, S., 2016, Common Side Effects of Clozapine and Their Management, *Intenational Journal of Emergency Mental Health and Human Resilience*, Vol. 18, No. 4, 1-6.
- Janoutova, J., Janackova, P., Sery, O., Zeman, T., Ambroz, P., Kovalova, M., Varechova, K., Hosak, L., Jirik, V., and Janout V., 2016, Epidemiology and Risk Factors of Schizophrenia, *Neuroendocrinology Letters*, 37(1), 1-8.
- Jeffrey, K.A., 2006, *Meyler's Side Effectt of Dugs 15th Edition*, Oxford, United Kingdom, cit Yulianty, M.D., Cahaya, N., Srikartika, V.M., 2017, Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan, *Jurnal Sains Farmasi & Klinis*, 3(2), 153-164.
- Jones, P., & Buckley, P., 2006, *Schizophrenia*, Mosby, London.
- Josiassen, R.C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W.W., Shaughnessy, R.A., 2005, Clozapine Augmented With Risperidone in The Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial, *Am J Psychiatry*, 162(1), 130-136.
- Kementerian Kesehatan Republik Indonesia, 2018, *Riset Kesehatan Dasar Republik Indonesia*, Kementerian Kesehatan, Jakarta.

- Khokhar, J.Y., Henricks, A.M., Sullivan, E.D.K., and Green, A. I., 2018, Chapter Seven - Unique Effects of Clozapine: A Pharmacological Perspective, *Advances in Pharmacology*, Vol 82 Page 137-162.
- Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins. D.O., and Kreyenbuhl, J., 2004, *Practice Guideline for The Treatment of Patients With Schizophrenia*, Second Ed, 1-184, American Psychiatric Association, U.S.
- Lemeshow, S., Hosmer, Jr., Klar, J., and Iwanga, S.K., 1997, *Adequacy of Sample Size in Health Study*, John Wiley & Sons Ltd, England.
- Maslim, R., 2001, *Diagnosis Gangguan Jiwa*, Bagian Ilmu Kedokteran Jiwa Fakultas Kedokteran Unika Atma Jaya, Jakarta.
- Naheed, M., & Green, B., 2001, Focus on Clozapine, *Current Medical Research And Opinion*, Volume 17, NO. 3, 223–229.
- Naqvi, I., Murtaza, M., Nazir, M., & Naqvi, H., 2010, Gender Difference in Age at Onset of Schizophrenia: A Cross Sectional Study from Pakistan, *J Pak Med Assoc*, 60(10), 886-889.
- Norman, S.M., Sullivan, K.M., Liu, F., Dipaula, B.A., Jose, P.A., Kitchen, C.A., Feldman, S.M., Kelly, D.L., 2017, Blood Pressure and Heart Rate Changes During Clozapine Treatment, *The Psychiatric Quarterly*, 88(3), 545-552.
- Ochoa, S., Usall, J., Cobo, J., Labad, X., Kulkarni, J., 2012, Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review, *Schizophrenia Research and Treatment*, Volume 2012, 1-9.
- Okhuijsen-Pfeifer, C., Huijsman, E., Hasan, A., Sommer, I., Leucht, S., Kahn, R. S., & Luykx, J. J. (2018). Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. *Acta psychiatrica Scandinavica*, 138(4), 281–288.
- Perhimpunan Dokter Spesialis Kedokteran jiwa Indonesia (PDSKJI) 2011, *Konsensus Penatalaksanaan Gangguan Skizofrenia*, Jakarta.
- Permatasari, V.D., 2016, Pola Penggunaan Antipsikotik Pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Grhasia Yogyakarta Tahun 2014, *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., and Teehanm, M., 2017, Guidelines for the Pharmacotherapy of Schizophrenia in Adults, *Canadian Schizophrenia Guidelines*, 62, 604-616.

- Reverger, M.J., 2012, Perbandingan Performa Fungsi Pasien Skizofrenia yang Mendapat Terapi Tunggal dengan Terapi Kombinasi Antipsikotika di Rumah Sakit Cipto Mangunkusumo (Periode Desember 2011-Mei 2012), *Tesis*, Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Sacchetti, E., Grunze, H., Leucht, S., Vita, A., 2015, Long-Acting Injection Antipsychotic Medications in The Management of Schizophrenia, *Evidence-based Psychiatric Care*, 1, 27-36.
- Saputri, R.K., 2018, Evaluasi Rasionalitas Penggunaan Antipsikotik Pada Pasien Skizofrenia di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Tahun 2016, *Skripsi*, Fakultas Farmasi, Universitas Setia Budi, Surakarta.
- Sernyak, M.J., Gulanski, B., Leslie, D.L., Rosenheck, R., 2003, Undiagnosed Hyperglycemia in Clozapine-treated Patients With Schizophrenia, *The Journal of Clinical Psychiatry*, 64(5), 605-608.
- Sinaga, B.R., 2007, *Skizofrenia dan Diagnosis Banding*, Balai Penerbit FKUI, Jakarta.
- Subramanian, S., Vollm, B.A., & Huband, N., 2017, Clozapine Dose for Schizophrenia, *Cochrane Database of Systematic Reviews*, <https://doi.org/10.1002/14651858.CD009555.pub2>.
- Wiramihardja, S.A., 2015, *Pengantar Psikologi Abnormal*, Edisi Revisi, Refika Aditama, Bandung cit. Fadilla, A.R., & Puspitasari, R.M., 2016, Evaluasi Ketepatan Penggunaan Antipsikotik Pada Pasien Skizofrenia Rawat Inap, *Saintesch Farma*, 9(1), 41-46.
- Yulianty, M.D., Cahaya, N., Srikartika, V.M., 2017, Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan, *Jurnal Sains Farmasi & Klinis*, 3(2), 153-164.